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Abstract
Multiple sclerosis (MS) is a progressive demyelinating disease presenting with
a relapsing-remitting course and affects large areas of the brain and the spinal
cord. Surgical stress often induces exacerbation of MS symptoms. It is mandatory
to prepare the MS patient very carefully for the surgery and anaesthesia with
an effective premedication and an effective postoperative analgesia following
a safe and minimal-risk anaesthesia management. In recent reports, results of
general and regional anaesthesia in MS patients have been discussed. To our
knowledge this is the first case report of the use of desflurane anaesthesia in
a patient with MS. In conclusion, desflurane anaesthesia is a safe and useful
method for MS patients.
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Introduction
Multiple sclerosis (MS) is a progressive demyelinating disease presenting
with a relapsing-remitting course [1]. High doses of corticosteroids used
in the treatment of this disease may cause avascular necrosis in the
femoral head. Surgical stress often induces exacerbation of MS symptoms.
Therefore, effective anaesthesia is required for anaesthetic management
in cases of MS [2, 3]. We aimed to report the desflurane anaesthesia that
we performed in an MS patient operated on for total hip replacement. To
our knowledge this is the first case of desflurane anaesthesia in an MS
patient in the literature.
Case report
A 31-year-old male patient with MS for 11 years was planned to have
a total hip prosthesis replacement for femoral head avascular necrosis due
to long-term steroid intake. He had not experienced any attacks for the
last 2 years. He was operated on for avascular necrosis of the other hip
under spinal anaesthesia two years ago without any problems according
to the patient history. In his preoperative examination, motor strength
was -5/5 on the left side, deep tendon reflexes were hyperactive, plantar
skin reflexes were bilaterally nonchalant, and he had neurogenic bladder.
Other physical examination and laboratory findings were normal. 5 mg 
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Copyright © 2010 Termedia & Banachof midazolam was administered intramuscularly
before taking the patient into the patient room.
Routine monitoring was performed in the operating
room. 15 mg of etomidate, 1 μg/kg of remifentanil,
and 7 mg of vecuronium bromide were used in
anaesthesia induction and the patient was
connected to a mechanical ventilator following
tracheal intubation. Continuation of anaesthesia
was performed with 0.2 μg/kg/m remifentanil
infusion and 5-6% concentration of desflurane in
N2O and O2 mixture. When the surgeon began skin
closure remifentanil infusion was stopped and
70 mg of dolantin was administered intramu  -
scularly. Haemodynamic findings were stable
throughout the process and the patient recovered
and was extubated at the end of surgery normally.
The postoperative analgesia regimen was ordered
in a conventional manner with non-steroid anti-
inflammatory and opioid analgesic drugs. He did
not have any symptoms or an attack due to MS
during hospitalization. 
Discussion
To our knowledge this is the first case report of
the use of desflurane anaesthesia in a patient with
MS. Also, this is the first case report in which
remifentanil was used except for one case in which
remifentanil was used for postoperative intravenous
patient-controlled analgesia [1]. 
It was reported that MS attacks might not only
occur spontaneously but also in stressful conditions,
infection [2], pregnancy [3], following a surgical
procedure and under anaesthesia [4]. For these
reasons, it is mandatory to prepare the patient very
carefully for the surgery and anaesthesia with an
effective premedication and an effective
postoperative analgesia following a safe and
minimal-risk anaesthesia management [5]. In recent
reports, results of general and regional anaesthesia
in MS patients have been discussed. Unfortunately
there is not a controlled clinical trial comparing
general and regional anaesthesia procedures in MS
patients. There are a few retrospective studies and
case reports in the literature. Most of the case
reports are obstetric. It is possible to find reports
about the advantages and disadvantages of
neuraxial blocks in the literature. According to many
authors, using regional anaesthesia for MS patients
is still a matter of confusion [4, 6, 7]. However, it is
not yet respected as a contraindication. Kyatta et
al. [8] reported that hypotension resistant to
hydration and vasopressors occurred in all 4 MS
patients who received regional anaesthesia in
a total of 56 MS patients in 10-year follow-up. They
did not comment on times of neural blockade, and
speculated that the local anaesthetic may have
damaged the spinal cord or much more may have
been taken because of demyelization. Under central
neural block, MS attacks may be correlated with
local anaesthetic. Is it possible that there is greater
uptake of local anaesthetics into the spinal cord
following subarachnoid, epidural or paravertebral
blocks in patients with MS? This effect has a much
greater risk in spinal anaesthesia than in epidural
anaesthesia because an intrathecal local
anaesthetic may directly bathe the nerve roots at
higher concentrations [9]. In that study, LA in the
white matter of the spinal cord was found 3-4 times
more in the spinal anaesthesia than epidural. Local
anaesthetic toxicity in demyelinating spinal nerves
may increase complications such as acute spinal
syndrome, paralysis and bladder dysfunction.
Brendan et al. [10] reported a prolonged central
block occurring with flaccid paralysis in both legs,
hypotension, and urinary retention following
paravertebral combined with general anaesthesia
in a patient with undiagnosed MS. They speculated
that it was due to abnormal uptake of the LA into
demyelinated nerves. Additionally, when regional
block combines with general anaesthesia,
characteristics of the block and neurological
complications are not recognized. Borgeat et al. [11]
reported severe plexopathy following brachial plexus
block in an MS patient. That case showed that
neurological complications can be seen following
not only central neural block but also peripheral
block. Bamford et al. [4] concluded that spinal
anaesthesia should be the final choice in MS
patients. Bader AM et al. [5] reported a 5-year
retrospective prospective combined study about
MS which applied epidural LA for vaginal delivery,
and they did not find any difference in safety
between epidural and general anaesthesia when
bupivacaine concentration was equal or under
0.25%. Higher doses were reported to be
responsible for an increase in relapse rates. 
A common problem in regional block is
unpredictable abnormal uptake of LA due to
demyelization of the spinal cord and nerves, and
complications are associated with that according
to its severity. Such problems are hypotension,
prolonged neural blockade, flaccid paralysis, urinary
retention, and acute spinal syndrome. Additionally,
the volume and concentration of LA applied may
be important. In this case, we tended to use general
anaesthesia because of the controversy about
regional anaesthesia in MS patients. It was reported
that some drugs, such as TPS ve Sch, have the
potential to cause an exacerbation. In addition, in
all general procedures body temperature might be
increased [12]. However, drugs such as sevoflurane
and propofol have been used before without any
problems [13-15]. 
There are no reports on desflurane anaesthesia
in MS patients in the literature. Desflurane is an
inhalation anaesthetic with a rapid onset and
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reflexes return more quickly than with sevoflurane
[16]. Moreover, it was realized that sevoflurane has
more toxic metabolites and has more damaging
effects on the kidneys [17]. Comparing the inhalant
agents, we think that the most appropriate agent
is desflurane. 
We used remifentanil as an induction and
perioperative analgesic. Remifentanil, also a strong
analgesic, is a suitable agent for stable anaesthesia
with a rapid onset and a short half-life with plasma
esterases [18]. Because of the short duration of
action, a combination of propofol and remifentanil
seems to be an alternative method, but
hypotension and bradycardia may occur. In lower
doses, it is possible that an MS attack may occur
because of lack of an effective anaesthesia.
In conclusion, we believe that general
anaesthesia has less risk of complications than
regional methods in MS patients and desflurane is
a safe agent to use in these patients.
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